NASDAQ : NAUT
Nautilus Biotechnology, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.73 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 347.73M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 347.73M |
| Enterprise Value | 287.89M |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 127.37M |
| Shares Outstanding | 127.37M |
| Shares Change (YoY) | +0.58% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 32.18% |
| Owned by Institutions (%) | 27.25% |
| Float | 67.58M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 820.11 |
| Forward PS | 103.48 |
| PB Ratio | 2.98 |
| P/TBV Ratio | 2.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 678.99 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 9.25 |
| Quick Ratio | 8.87 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -41.01% |
| Return on Assets (ROA) | -22.88% |
| Return on Invested Capital (ROIC) | -23.59% |
| Return on Capital Employed (ROCE) | -46.02% |
| Weighted Average Cost of Capital (WACC) | 7.68% |
| Revenue Per Employee | $3,339 |
| Profits Per Employee | -$461,283 |
| Employee Count | 127 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.73 |
| 52-Week Price Change | +93.62% |
| 50-Day Moving Average | 1.59 |
| 200-Day Moving Average | 2.12 |
| Relative Strength Index (RSI) | 57.43 |
| Average Volume (20 Days) | 12,296,707 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.62M |
| Short Previous Month | 5.77M |
| Short % of Shares Out | 4.41% |
| Short % of Float | 8.32% |
| Short Ratio (days to cover) | 0.69 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 424,000 |
| Gross Profit | 385,000 |
| Operating Income | -64.05M |
| Pretax Income | -58.58M |
| Net Income | -58.58M |
| EBITDA | -62.76M |
| EBIT | -64.05M |
| Loss Per Share | -$0.46 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 86.58M |
| Total Debt | 26.74M |
| Net Cash | 59.84M |
| Net Cash Per Share | $0.47 |
| Equity (Book Value) | 116.56M |
| Book Value Per Share | 0.92 |
| Working Capital | 80.48M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -52.48M |
| Capital Expenditures | -2.65M |
| Depreciation & Amortization | 1.29M |
| Net Borrowing | n/a |
| Free Cash Flow | -55.14M |
| FCF Per Share | -$0.43 |
Margins
| Measure | Value |
|---|
| Gross Margin | 90.80% |
| Operating Margin | -15,105.66% |
| Pretax Margin | -13,816.75% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.58% |
| Shareholder Yield | -0.58% |
| Earnings Yield | -16.92% |
| FCF Yield | -15.86% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $4.00 |
| Price Target Difference | 46.52% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.32 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |